Methodist Journal

IN THIS ISSUE

Lipids and Lipoproteins

Vol 15, Issue 1 (2019)


FEATURED GUEST EDITOR

ISSUE INTRO

Lipids and Cardiovascular Disease: Putting it All Together

See More
RECOGNITIONS

Guest Editors Henry Pownall and Antonio Gotto Offer Insight and Expertise on the topic of Lipids and Cardiovascular Disease

See More

REVIEW ARTICLES See More

Cholesterol: Can’t Live With It, Can’t Live Without It

How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines

Statins: Then and Now

Poststatin Lipid Therapeutics: A Review

HDL and Reverse Cholesterol Transport Biomarkers

Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability

High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes

Gene Delivery in Lipid Research and Therapies

CASE REPORTS See More

Device-Related Thrombus: A Reason for Concern?

Retained Coronary Balloon Requiring Emergent Open Surgical Retrieval: An Uncommon Complication Requiring Individualized Management Strategies

Loperamide Mimicking Brugada Pattern

Reversed Pulsus Paradoxus in Right Ventricular Failure

MUSEUM OF HMH MULTIMODALITY IMAGING CENTER See More

Transcatheter Embolization of a Persistent Vertical Vein: A Rare Cause of Left-to-Right Shunt and Right-Sided Heart Failure

CLINICAL PERSPECTIVES See More

EXCERPTA

Talking Statins with Antonio Gotto

POINTS TO REMEMBER

Lipids and Renal Disease

EXCERPTA

Addressing the Feedback Loop Between Depression, Diabetes, and Cardiovascular Disease

POINTS TO REMEMBER

The Kidney as an Endocrine Organ

EDITORIALS

Addressing the Underrepresentation of Women in Cardiology through Tangible Opportunities for Mentorship and Leadership

Vol 14, Issue 1 (2018)

Article Full Text

REVIEW ARTICLES

Chronic Total Occlusion Coronary Intervention: In Search of a Definitive Benefit

Jump to:
Article Citation:

Shah A. Chronic Total Occlusion Coronary Intervention: In Search of a Definitive Benefit. Methodist DeBakey Cardiovasc J. 2018;14(1):52-59.

doi: 10.14797/mdcj-14-1-50

Abstract

Percutaneous coronary intervention (PCI) of chronic coronary total occlusion is the latest frontier in percutaneous intervention. There are vast improvements in the initial success and safety of the procedure as well as a better understanding of appropriateness and benefits. Advances in technology and skill allow for increased utilization of PCI in cases of chronic coronary total occlusion, with benefits regarding symptoms and quality of life. Percutaneous coronary intervention for chronic coronary total occlusion can correct ischemia and achieve complete revascularization while avoiding traditional coronary bypass grafting, although survival benefits remain unclear.

Keywords
chronic total occlusion , percutaneous coronary intervention , complete revascularization , angina , CAD ,  interventional cardiology ,  ischemia ,  ischemic heart disease

BACKGROUND

The field of coronary interventions has advanced tremendously in the last 2 decades and is particularly evident with regard to chronic total occlusion (CTO) percutaneous coronary intervention (PCI). There are vast improvements in the procedure’s safety and initial success as well as a better understanding of its benefits and patient suitability. Even so, many doubts and questions remain as to the benefits of CTO PCI. It has been described that the procedure offers symptomatic benefits and improves quality of life, but this is based more on observational studies rather than on randomized clinical trials.1 CTO PCI is considered by most to be a long, expensive, technically difficult procedure with low success and high complication rates. Also, CTO is perceived as a benign and stable lesion since it does not progress or cause a heart attack. If there are adequate collateral arteries, what is the need for revascularization?

Coronary CTO is defined as a totally occluded coronary artery with TIMI (Thrombolysis in Myocardial Infarction) 0 flow for at least 3 months.2 It is reported to occur in 15% to 23% of patients who undergo coronary angiograms and is the most common feature leading to coronary bypass surgery as a treatment recommendation for revascularization.3,4 The Bypass Angioplasty Revascularization Investigation (BARI) registry suggested that CTO was a powerful predictor of referral for coronary artery bypass graft (CABG) and treatment with medical therapy. When a CTO was present in the BARI trial, 10% received PCI, 40% received CABG, and 50% received medical therapy. When a CTO was not present, the numbers shifted to 35% PCI, 30% CABG, and 35% medical therapy.5 Interestingly, there are many times during surgery that CTO arteries are not amenable for bypass (e.g., too small or diseased arteries). For example, in the SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) CTO substudy, only 68% of those sent to surgery actually underwent CABG, leading to 49.6% overall complete revascularization in the CTO subset.6

In the past, PCI for a CTO had low success rates of about 50%, which meant that CABG was the gold standard in terms of complete revascularization. Patients with a failed CTO PCI had higher rates of CABG at 2 years compared to patients with successful procedures (P < .001). After adjustment, successful CTO PCI remained associated with a lower risk for CABG surgery (HR 0.14; 95% CI, 0.08-0.24; P < .01).7 Novel PCI techniques have helped to overcome this barrier by improving PCI success rates to > 85% at some centers.8,9

TECHNIQUES

The significant improvement in coronary CTO PCI success rates is due to a variety of reasons, with the most important being technological advances. Wire designs with higher crossing power lead to higher success rates. Polymer-jacketed wires are used in most cases, including the most successfully crossed cases.10 Crossing catheters are designed to advance in intimal and subintimal spaces, allowing for subsequent exchange to support wires and, eventually, low-profile balloons.

There are primarily four techniques for CTO PCI, including (1) antegrade wire escalation, (2) antegrade dissection and reentry (ADR), (3) retrograde wire escalation, and (4) retrograde dissection and reentry. The typical ADR technique uses the Stingray LP (Boston Scientific) wire and balloon. This allows the wire to reenter in the luminal space after having traversed beyond the CTO segment in the subintimal space. If the antegrade techniques are unsuccessful, retrograde wire crossing using septal or epicardial “interventional” collaterals can be used (Figure 1). Skilled operators can yield high crossing rates with dissection reentry via the retrograde approach, often using a hybrid CTO crossing algorithm for guidance (Figure 2).11

Figure 1. (A, B) Antegrade wire reentry technique using a Stingray (Boston Scientific) balloon in mid LAD (left anterior descending). (C, D) Retrograde wire escalation technique using septal collaterals from circumflex to LAD.
Figure 2. Hybrid algorithm for chronic total occlusion percutaneous coronary intervention. Reprinted with permission.11
Success rates depend not only on operator experience but also on anatomical features. Length, calcification, tortuosity, and an ambiguous cap are features that will affect initial success rates. The PROGRESS CTO registry (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) has shown high success rates of 91% and low major complication rates of 1.7% for CTO interventions performed at high-volume centers with skilled operators.12

Table 1. First, second, and successful strategies employed during hybrid chronic total occlusion (CTO) percutaneous coronary intervention (PCI). ADR: antegrade dissection and reentry; AWE: antegrade wire escalation; RDR: retrograde dissection and reentry; RWE: retrograde wire escalation

As shown by the OPEN CTO investigators, a successful CTO program requires skill and knowledge of all four techniques (Table 1).8 Early complication rates are slightly higher than those of routine PCI, regardless of which technique is used, but can be properly identified and managed by experienced sites. The OPEN CTO registry is a comprehensive, core-lab adjudicated, single-arm, multicenter registry of 1,000 consecutive patients who underwent CTO PCI with the hybrid approach. The technical success was 86%, in-hospital and 1-month mortality were 0.9% and 1.3%, respectively, and 48 patients (4.8%) had perforations requiring treatment. Periprocedural myocardial infarction (MI) was observed in 26 patients (2.6%) and in-hospital repeat PCI occurred in one (0.1%). Seven patients overall (0.7%) were referred for emergent surgery, and no in-hospital strokes were identified. Acute kidney injury was identified in eight patients (0.8%), and there were three (0.3%) major bleeding events that required treatment.

The durability of second-generation drug-eluting stents has made CTO PCI a viable alternative to CABG, especially compared to saphenous vein graft bypass. The EXPERT CTO trial used everolimus-eluting stents for CTO PCI in 250 patients.13 At 1 year, clinically driven target lesion revascularization was seen in 6.3% of patients, and cardiac death occurred in 1.9%. Definite subacute stent thrombosis (ST) was identified in two patients (0.9%), with no definite events observed after 30 days. Late probable ST was identified in one patient (0.5%).

SYMPTOMATIC BENEFIT

Determining which individuals are clinically appropriate and will benefit from CTO PCI requires more research. However, there are several well-established clinical benefits. Improved Seattle Angina Questionnaire (SAQ) angina frequency score and quality of life score have been well recognized after CTO interventions.14 This improvement has been confirmed in many registries, capturing a clinically relevant end point that compels patients to seek a cardiologist in the first place—to control or avoid altogether their disabling symptoms. Sometimes patients attribute their fatigue and dyspnea to old age or poor fitness, but after revascularization, they recognize how much of their limitation was caused by the occluded artery. In the OPEN CTO registry,8 mean ± SEM SAQ quality of life scores improved from 49.4 ± 0.9 to 75.0 ± 0.7 (P < .01), mean Rose Dyspnea Scale scores improved (decreased) from 2.0 ± 0.1 to 1.1 ± 0.1 (P < .01), and physician health questionnaire scores for depression improved (decreased) from 6.2 ± 0.2 to 3.5 ± 0.1 (P < .01) at 1 month. After adjusting for baseline differences, the mean group difference between successful and unsuccessful CTO PCI in SAQ quality of life was 10.8 (95% CI, 6.3-15.3; P < .001).

IMAGING GUIDANCE

Imaging studies are playing a pivotal role in guiding CTO PCI. Information regarding wall motion, ischemia, and viability is priceless in clinical decision making since symptoms are often nonspecific. There is also a growing use of coronary computed tomography angiography for better visualization of the arterial wall, occluded segment, and its course.

Figure 3. (A) Kaplan–Meier survival for patients by residual ischemia, including 0%, 1% to 4.9%, 5% to 9.9%, and ? 10% ischemic myocardium, respectively, after 6 to 18 months of combined percutaneous coronary intervention and optimal medical therapy or optimal medical therapy alone. Reprinted with permission.15

Image-guided PCI is especially relevant given that a large proportion of patients with CTOs are treated with medical therapy alone. The COURAGE trial demonstrated that optimal medical therapy (OMT) is inferior to combined OMT and PCI in reducing ischemic burden, anginal class, and reliance on nitrate therapy. In a nuclear substudy, it was shown that a higher proportion of left ventricular (LV) ischemia on stress testing was associated with higher rates of death and MI. Thus, while symptoms may be controlled by medical therapy, evidence is in favor of CTO PCI in asymptomatic patients with residual ischemic burden > 10% for the benefit of survival (Figure 3).15

Although it is thought that retrograde collateralization provides adequate blood flow to reduce ischemia, Sachdeva et al. reported that the patients with successfully wired CTOs all had physiologically significant ischemia as assessed by fractional flow reserve (FFR), irrespective of the angiographic appearance of collaterals.16 In other words, no CTOs are adequately collateralized to correct ischemia. Since FFR of an infarcted bed will be negative, it is critically important to assess viability in myocardium subtended by a CTO, especially among asymptomatic patients.

Bucciarelli-Ducci et al. explored the possible use of cardiac magnetic resonance imaging for guiding CTO PCI.17 In their study, 32 patients were selected for recanalization based on the presence of significant inducible perfusion deficit and myocardial viability within the CTO region. There was a low incidence of symptoms since the majority of patients had limited or no angina (Canadian Cardiovascular Society classes I and II; n = 26; 81%) and New York Heart Association functional classes I and II (n = 21; 66%). After PCI, myocardial perfusion reserve (MPR) in the CTO region improved significantly to 2.3 ± 0.9 (P = .02) versus baseline, with complete or near-complete resolution of CTO-related perfusion defect in 90% of patients. Remote territory MPR was unchanged after PCI (2.5 ± 1.2; P = NS vs baseline). Three months after CTO PCI, LV ejection fraction had increased from 63 ± 13% to 67 ± 12% mL (P < .0001) and end-systolic volume decreased from 65 ± 38 to 56 ± 38 mL (P < .001). Despite minimal postprocedural infarction from distal embolization and side branch occlusion in 8 of 32 patients (25%), the total SAQ score improved from a median of 54 (range 45-74) at baseline to 89 (range 77-98) after CTO recanalization (P < .0001).

SURVIVAL BENEFIT

Presence of CTO and Mortality

Figure 4. Mortality in 1,417 patients with STEMI treated with primary percutaneous coronary intervention (*log-rank test for CTO vs no CTO). Reprinted with permission.18 MVD: multivessel disease; CTO: chronic total occlusion

In the setting of acute ST-elevation myocardial infarction (STEMI), the presence of a CTO is an independent predictor of mortality. Van der Schaff et al.18 showed mortality rates in patients with single-vessel disease, multivessel disease (MVD), and a CTO to be 8%, 16%, and 35%, respectively. Although MVD was an independent predictor of mortality, this was not the case when CTO was included in the model. Chronic total occlusion was a strong and independent predictor for 1-year mortality in patients with STEMI treated with PCI (Figure 4).

Batalle et al.19 showed that CTO is an independent predictor of mortality in patients presenting with cardiogenic shock. Mortality was substantially high in patients with one CTO and exceedingly higher in those with more than one. The prevalence of one or more than one CTO in a non–infarct-related artery was 23% and 5%, respectively, among patients with shock compared with 6% and 0.5% in patients without shock (P < .001). Thirty-day mortality was 100% in shock patients with more than one CTO, 65.6% with one CTO, and 40.2% in patients without CTO (P < .001).

The association between CTO lesions and increased mortality still leaves important questions as to whether or not CTO revascularization alters that risk. Estimates of potential survival benefits with CTO PCI are limited by the available data, which consists mainly of observational series and registries (Table 2).

Table 2. Major registries and clinical trials for chronic total occlusion.
Table 2b. Registries continued.
Table 2c. Registries continued.
Table 2d. Registries continued.

CTO PCI and Survival Benefit

Figure 5. Kaplan-Meier estimates of survival rates in patients with successful chronic total occlusion (CTO) percutaneous coronary intervention (PCI) (blue) versus unsuccessful CTO PCI (red). Reprinted with permission.7

The Veterans Affairs Clinical Assessment Reporting and Tracking program examined outcomes in 2,394 consecutive veterans who underwent elective CTO PCI from 2007 to 2013.7 Cumulative 2-year survival curves demonstrated slightly higher unadjusted survival among patients with successful versus failed elective CTO PCIs (P = .05). After adjustment for differences in baseline characteristics, successful CTO PCI remained an independent predictor of 2-year survival (HR 0.67; 95% CI, 0.47-0.95; P = .02) (Figure 5).

A few randomized controlled trials have attempted to assess outcomes of CTO PCI in patients with stable disease. Unlike registries that are focused and driven by experienced CTO PCI operators, randomized controlled trials are limited by excessive scrutiny, less-symptomatic patients (in general), limited funding, and slow enrollment. The recently presented DECISION CTO trial, which tested OMT with or without stenting for CTO, had to stop enrolling after 834 patients due to slow enrollment; it also suffered from high crossover rates of almost 20%.20 The study concluded that OMT is noninferior to CTO PCI with respect to the primary composite end point of death, MI, stroke, or any revascularization at 3 years. In addition, quality of life indices were comparable between the two groups.

The EUROCTO trial included 407 patients with a CTO from 26 participating centers and randomized them 2:1 to PCI or OMT.21 The rate of major adverse cardiac and cerebrovascular events at 12 months was similar between both arms (PCI 5.2% vs OMT 6.7%; P = .52), although there was significant improvement in angina frequency with CTO PCI over OMT (P = .009). The trial was terminated early with only 40% of the planned enrollment.

CLINICAL DECISION MAKING

The American College of Cardiology/American Heart Association guideline for coronary intervention provides a class IIa rating for CTO PCI, stating that “PCI of a chronic total occlusion in patients with appropriate clinical indications and suitable anatomy is reasonable when performed by operators with appropriate expertise” (Level of Evidence B).22 Before proceeding with revascularization, however, it is important to fully understand the burden of symptoms and risk attributable to CTO as well as the possible benefits of OMT.

The challenge of incomplete revascularization remains in patients with multivessel coronary artery disease who undergo PCI. This is due to variety of factors. Operators treating patients with CTOs often revascularize coronary vessels that were not supplying areas of ischemia detected on stress imaging.23 Although non-CTO PCI may potentially augment collateral flow to the CTO territory, it may be insufficient in alleviating ischemia and anginal symptoms due to the CTO. Resistance to treating the CTO lesion may reflect operator perceptions about the higher risks associated with CTO PCI, a lack of skills and equipment for technically more complex procedures, and the greater investment of time and resources required for successful treatment.

There is also the issue of bias, in which some believe an occluded epicardial coronary vessel is not as worthy of PCI as is a vessel with severe stenosis. One can argue that neither lesion anatomy has been associated with mortality reduction except maybe lesions in the left main or proximal left anterior descending arteries. Interestingly, during CABG, a CTO is expected to be bypassed with the hope of achieving complete revascularization. If CTO PCI revascularization is not a priority, why do we insist on bypassing a CTO segment with adequate collaterals during bypass surgery?

Assessing symptoms is another consideration in clinical decision making because, more often than not, the only symptoms reported by the patient are fatigue and/or shortness of breath but not chest pain. Patients also tend to adapt to those limitations and learn to live with them, often unknowingly, similar to living with a bad knee or back. Cardiologists are trained to pursue life-saving procedures, and anything less—such as improved quality of life or symptoms—is deemed unworthy, especially in research settings. Therefore, selecting the right patient who will benefit from CTO PCI is extremely important. A smart, detailed assessment of symptoms is essential in patients with an active lifestyle and good life expectancy. Imaging studies should be used to determine how the CTO impacts ischemia and myocardial viability. Furthermore, patient education with regard to risks, benefits, and options is vital.

Selecting the right CTO PCI operator is just as vital, as inadequate techniques often lead to higher failure and lower success rates. The institution has an obligation to provide CTO patients with a highly skilled operator who has expertise in all types of CTO PCI techniques. Various registry outcomes with high CTO volume operators have suggested procedural success rates greater than 80% as a benchmark.

SUMMARY

Chronic total occlusion PCI is the latest frontier in the evolution of percutaneous revascularization. The last decade has seen tremendous growth in terms of operator skill and device technology. Barriers to widespread adoption of CTO PCI may include biases that influence operator and clinician decision-making. CTO PCI has often been equated to a box of chocolates, where, in the words of Forrest Gump, “you never know what you’re gonna get.” One thing is for certain: when successful, CTO PCI allows for complete revascularization while avoiding CABG. Technical success rates at experienced centers exceed 85%, and it clearly benefits patients by alleviating symptoms and improving quality of life. There is significant evidence of improvement in LV function and reduction of ischemia. Despite strong arguments, however, convincing proof of survival benefit remains elusive.

KEY POINTS

  • Technical success of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has improved with experienced operators to > 80%.
  • Fractional flow reserve confirms persistent ischemia in CTO segments despite collaterals that appear adequate.
  • The presence of CTO in a noninfarct artery during a myocardial infarction is associated with high mortality.
  • Chronic total occlusion PCI is shown to improve symptoms, reduce ischemia, and improve left ventricular function.
  • Convincing proof of survival benefit from CTO PCI remains elusive.
Conflict of Interest Disclosure

Dr. Shah serves in an advisory role for Abbott Vascular, Boston Scientific, Medtronic, and AstraZeneca.

References
  1. Bardaji A, Rodriguez-Lopez J, Torres-Sanchez M. Chronic total occlusion: To treat or not to treat. World J Cardiol. 2014 Jul 26;6(7):621-9.
  2. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial. Phase 1 findings. N Engl J Med. 1985 Apr 4;312(14):932-6.
  3. Luo C, Huang M, Li J, et al. Predictors of interventional success of antegrade PCI for CTO. JACC Cardiovasc Imaging. 2015 Jul;8(7):804-13.
  4. Grantham JA, Marso SP, Spertus J, House J, Holmes DR Jr, Rutherford BD. Chronic total occlusion angioplasty in the United States. JACC: Cardiovascular Interventions. 2009 Jun;2(6):479-86.
  5. Christofferson RD, Lehmann KG, Martin GV, Every N, Caldwell JH, Kapadia SR. Effect of chronic total coronary occlusion on treatment strategy. Am J Cardiol. 2005 May 1;95(9):1088-91.
  6. Farooq V, Serruys PW, Garcia-Garcia HM, et al. The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: the SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial. J Am Coll Cardiol. 2013 Jan 22;61(3):282-94.
  7. Tsai TT, Stanislawski MA, Shunk KA, et al. Contemporary Incidence, Management, and Long-Term Outcomes of Percutaneous Coronary Interventions for Chronic Coronary Artery Total Occlusions: Insights From the VA CART Program. JACC Cardiovasc Interv. 2017 May 8;10(9):866-75.
  8. Sapontis J, Salisbury AC, Yeh RW, et al. Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty: A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). JACC Cardiovasc Interv. 2017 Aug 14;10(15):1523-1534.
  9. Maeremans J, Walsh S, Knaapen P, et al. The Hybrid Algorithm for Treating Chronic Total Occlusions in Europe: The RECHARGE Registry. J Am Coll Cardiol. 2016 Nov 1;68(18):1958-70.
  10. Karatasakis A, Tarar MN, Karmpaliotis D, et al. Guidewire and microcatheter utilization patterns during antegrade wire escalation in chronic total occlusion percutaneous coronary intervention: Insights from a contemporary multicenter registry. Catheter Cardiovasc Interv. 2017 Mar 1;89(4):E90-8.
  11. Brilakis ES, Grantham JA, Rinfret S, et al. A percutaneous treatment algorithm for crossing coronary chronic total occlusions. JACC Cardiovasc Interv. 2012 Apr;5(4):367-79.
  12. Christopoulos G, Karmpaliotis D, Alaswad K, et al. Application and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registry. Int J Cardiol. 2015 Nov 1;198:222-8.
  13. Kandzari DE, Kini AS, Karmpaliotis D, et al. Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization: Results From the EXPERT CTO Multicenter Trial (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions). JACC Cardiovasc Interv. 2015 May;8(6):761-769.
  14. Safley DM, Grantham JA, Hatch J, Jones PG, Spertus JA. Quality of life benefits of percutaneous coronary intervention for chronic occlusions. Catheter Cardiovasc Interv. 2014 Oct 1;84(4):629-34.
  15. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008 Mar 11;117(10):1283-91.
  16. Sachdeva R, Agrawal M, Flynn SE, Werner GS, Uretsky BF. The myocardium supplied by a chronic total occlusion is a persistently ischemic zone. Catheter Cardiovasc Interv. 2014 Jan 1;83(1):9-16.
  17. Bucciarelli-Ducci C, Auger D, Di Mario C, et al. CMR guidance for recanalization of coronary chronic total occlusion. JACC Cardiovasc Imaging. 2016 May;9(5)547-56.
  18. van der Schaaf RJ, Vis MM, Sjauw KD, et al. Impact of multivessel coronary disease on long-term mortality in patients with ST-elevation myocardial infarction is due to the presence of a chronic total occlusion. Am J Cardiol. 2006 Nov 1;98(9):1165-9.
  19. Bataille Y, Déry JP, Larose É, et al. Deadly association of cardiogenic shock and chronic total occlusion in acute ST-elevation myocardial infarction. Am Heart J. 2012 Oct;164(4):509-15.
  20. Park SJ. Optimal medical therapy with or without stenting for coronary chronic total occlusion: DECISION CTO. Paper presented at: ACC 2017: 66th Annual Scientific Session. 2017 Mar 18; Washington, D.C.
  21. Werner GS. A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions (EuroCTO). Paper presented at: EuroPCR 2017. 2017 May 18; Paris, France.
  22. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011 Dec 6;58(24):e44-122.
  23. Secemsky E, Gallagher R, Harkness J, et al. Target Vessel Revascularization and Territory of Myocardial Ischemia in Patients With Chronic Total Occlusions. J Am Coll Cardiol. 2017 Aug 29;70(9):1196-7.

Add Comments

Please login to dialogue with author.

Comments